B. Riley Securities Initiates Coverage On Arcturus Therapeutics with Buy Rating, Announces Price Target of $22
Benzinga Newsdesk 7 months ago
NewsPrice TargetInitiationAnalyst Ratings
B. Riley Securities analyst Mayank Mamtani initiates coverage on Arcturus Therapeutics (NASDAQ:ARCT) with a Buy rating and announces Price Target of $22.
B. Riley Securities analyst Mayank Mamtani initiates coverage on Arcturus Therapeutics (NASDAQ:ARCT) with a Buy rating and announces Price Target of $22.